Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including nausea, photo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC neurology 2022-06, Vol.22 (1), p.205-205, Article 205
Hauptverfasser:	Ailani, Jessica, McAllister, Peter, Winner, Paul K, Chakhava, George, Krog Josiassen, Mette, Lindsten, Annika, Sperling, Bjørn, Ettrup, Anders, Cady, Roger
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized Calcitonin Calcitonin Gene-Related Peptide CGRP Dosage and administration Double-Blind Method Drug therapy Eptinezumab Headache Headaches Humans Hyperacusis - drug therapy MBS Medicine, Preventive Migraine Migraine Disorders - drug therapy Migraine Disorders - prevention & control Monoclonal antibodies Nausea Pain Patients Photophobia - drug therapy Photophobia - etiology Placebos Preventive health services Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including nausea, photophobia, or phonophobia) compared with placebo when administered during a migraine attack. The objective of this exploratory analysis was to examine the earliest time points that eptinezumab separated from placebo (P
ISSN:	1471-2377 1471-2377
DOI:	10.1186/s12883-022-02714-1